242 related articles for article (PubMed ID: 29803615)
21. [A long-term follow-up study of 82 children with acute myeloid leukemia].
Ruan M; Qi BQ; Liu F; Liu TF; Liu XM; Chen XJ; Yang WY; Guo Y; Zhang L; Zou Y; Chen YM; Zhu XF
Zhonghua Er Ke Za Zhi; 2018 Oct; 56(10):730-734. PubMed ID: 30293275
[No Abstract] [Full Text] [Related]
22. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
23. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study.
Behringer B; Pitako JA; Kunzmann R; Schmoor C; Behringer D; Mertelsmann R; Lübbert M
Ann Hematol; 2003 Jul; 82(7):381-9. PubMed ID: 12756497
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
[TBL] [Abstract][Full Text] [Related]
25. Single monosomy as a relatively better survival factor in acute myeloid leukemia patients with monosomal karyotype.
Jang JE; Min YH; Yoon J; Kim I; Lee JH; Jung CW; Shin HJ; Lee WS; Lee JH; Hong DS; Kim HJ; Kim HJ; Park S; Lee KH; Jang JH; Chung JS; Lee SM; Park J; Park SK; Ahn JS; Min WS; Cheong JW;
Blood Cancer J; 2015 Oct; 5(10):e358. PubMed ID: 26473530
[TBL] [Abstract][Full Text] [Related]
26. Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.
Pigneux A; Harousseau JL; Witz F; Sauvezie M; Bene MC; Luquet I; Hunault-Berger M; Recher C; Lioure B; Himberlin C; Escoffre-Barbe M; Berthou C; Lissandre S; Fegueux N; Cahn JY; Jourdan E; Dreyfus F; Reiffers J; Milpied N; Ifrah N
J Clin Oncol; 2010 Jun; 28(18):3028-34. PubMed ID: 20479424
[TBL] [Abstract][Full Text] [Related]
27. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
Schoch C; Kern W; Schnittger S; Büchner T; Hiddemann W; Haferlach T
Haematologica; 2004 Sep; 89(9):1082-90. PubMed ID: 15377469
[TBL] [Abstract][Full Text] [Related]
28. Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients.
Wang S; Yuan X; Liu Y; Zhu K; Chen P; Yan H; Zhang D; Li X; Zeng H; Zhao X; Chen X; Zhou G; Cao S
J Transl Med; 2019 Mar; 17(1):101. PubMed ID: 30922329
[TBL] [Abstract][Full Text] [Related]
29. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
30. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.
Gardin C; Chevret S; Pautas C; Turlure P; Raffoux E; Thomas X; Quesnel B; de Revel T; de Botton S; Gachard N; Renneville A; Boissel N; Preudhomme C; Terré C; Fenaux P; Bordessoule D; Celli-Lebras K; Castaigne S; Dombret H
J Clin Oncol; 2013 Jan; 31(3):321-7. PubMed ID: 23248249
[TBL] [Abstract][Full Text] [Related]
31. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
[TBL] [Abstract][Full Text] [Related]
32. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.
Oriol A; Ribera JM; Esteve J; Guàrdia R; Brunet S; Bueno J; Pedro C; Llorente A; Tormo M; Besalduch J; Sánchez JM; Batlle M; Vivancos P; Carreras E; Vilà JM; Julià A; Sierra J; Montserrat E; Feliu E;
Haematologica; 2004 Jul; 89(7):791-800. PubMed ID: 15257930
[TBL] [Abstract][Full Text] [Related]
33. Low Platelet Counts at Diagnosis Predict Better Survival for Patients with Intermediate-Risk Acute Myeloid Leukemia.
Zhang Y; Gu H; Chen Q; Zhang Y; Cheng H; Yang J; Wang J; Hu X
Acta Haematol; 2020; 143(1):9-18. PubMed ID: 31167182
[TBL] [Abstract][Full Text] [Related]
34. Concomitance of monosomal karyotype with at least 5 chromosomal abnormalities is associated with dismal treatment outcome of AML patients with complex karyotype - retrospective analysis of Polish Adult Leukemia Group (PALG).
Wierzbowska A; Wawrzyniak E; Siemieniuk-Rys M; Kotkowska A; Pluta A; Golos A; Robak T; Szarawarska M; Jaskowiec A; Duszenko E; Rybka J; Holojda J; Grosicki S; Pienkowska-Grela B; Woroniecka R; Ejduk A; Watek M; Wach M; Mucha B; Skonieczka K; Czyzewska M; Jachalska A; Klonowska A; Iliszko M; Knopinska-Posluszny W; Jarmuz-Szymczak M; Przybylowicz-Chalecka A; Gil L; Kopacz A; Holowiecki J; Haus O
Leuk Lymphoma; 2017 Apr; 58(4):889-897. PubMed ID: 27561449
[TBL] [Abstract][Full Text] [Related]
35. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
[TBL] [Abstract][Full Text] [Related]
36. Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup.
Büchner T; Schlenk RF; Schaich M; Döhner K; Krahl R; Krauter J; Heil G; Krug U; Sauerland MC; Heinecke A; Späth D; Kramer M; Scholl S; Berdel WE; Hiddemann W; Hoelzer D; Hehlmann R; Hasford J; Hoffmann VS; Döhner H; Ehninger G; Ganser A; Niederwieser DW; Pfirrmann M
J Clin Oncol; 2012 Oct; 30(29):3604-10. PubMed ID: 22965967
[TBL] [Abstract][Full Text] [Related]
37. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype.
Mi Y; Xue Y; Yu W; Liu S; Zhao Y; Meng Q; Bian S; Wang J
Leuk Lymphoma; 2008 Mar; 49(3):524-30. PubMed ID: 18297530
[TBL] [Abstract][Full Text] [Related]
39. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
40. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
Tavor S; Rahamim E; Sarid N; Rozovski U; Gibstein L; Aviv F; Kirsner I; Naparstek E
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
